|
Demographics
|
|
Age, yrs
|
67
|
63
|
64
|
|
Sex, M/F
|
M
|
F
|
F
|
|
Anti-Mitochondrial Antibody
|
|
Titer by IF at diagnosis
|
1:40
|
1:160
|
1:160
|
|
Liver Enzymes at diagnosis
|
|
AP (N<145 IU/L)
|
67
|
134
|
71
|
|
GGT (N<35)
|
130
|
330
|
41
|
|
Hepatitis C Virus
|
|
Duration HCV+ status, yrs
|
19
|
19
|
15
|
|
Genotype
|
1a
|
1a
|
4
|
|
Treatment Naive
|
Yes
|
No
|
Yes
|
|
Treatment Regimen
|
LDV + SOF
|
LDV + SOF
|
SOF +RBV
|
|
RNA NAT, weeks post tx
|
<12 IU/ml (12)
|
ND (24)
|
ND (24)
|
|
Autoantibody Profile (Mitogen)
|
AMA-M2+, Anti-3E-BPO+
|
Anti-3E-BPO+, Anti-Ro52+
|
AMA-M2+, Anti-3E-BPO+
|
|
Fibroscan (fPa)
|
|
Pre-treatment with DAA
|
37.4
|
15.1
|
14.1
|
|
Post-treatment with DAA
|
19.8
|
12.3
|
No data
|
|
Ursodeoxycholic acid treatment
|
Yes
|
No (discontinued)
|
No
|
